PF-Atlas › Clinical Trials › NCT05504837
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
KB407 · Phase 1
Registry ID
NCT05504837
Phase
Phase 1
Status
Recruiting
Drug / intervention
KB407 (Nebulization)
Sponsor
Krystal Biotech, Inc.
Start
2023-06-30
Enrollment
20
Locations
6
About this trial
This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05504837 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.